241 results on '"Delcuratolo A"'
Search Results
2. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives
- Author
-
Turco, Fabio, Buttigliero, Consuelo, Delcuratolo, Marco Donatello, Gillessen, Silke, Vogl, Ursula Maria, Zilli, Thomas, Fossati, Nicola, Gallina, Andrea, Farinea, Giovanni, Di Stefano, Rosario Francesco, Calabrese, Mariangela, Saporita, Isabella, Crespi, Veronica, Poletto, Stefano, Palesandro, Erica, Di Maio, Massimo, Scagliotti, Giorgio Vittorio, and Tucci, Marcello
- Published
- 2024
- Full Text
- View/download PDF
3. Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis
- Author
-
Giovanni Farinea, Mariangela Calabrese, Federica Carfì, Isabella Saporita, Stefano Poletto, Marco Donatello Delcuratolo, Fabio Turco, Marco Audisio, Francesco Rosario Di Stefano, Marcello Tucci, and Consuelo Buttigliero
- Subjects
prostate cancer ,androgen receptor pathway inhibitor ,neuroendocrine tumors ,castration-resistant prostate cancer ,Cytology ,QH573-671 - Abstract
Neuroendocrine differentiation (NED) represents a possible androgen receptor pathway inhibitors (ARPI) resistance mechanism in metastatic castration resistance prostate cancer (mCRPC). As mCRPC with NED has been excluded from clinical trials evaluating ARPI efficacy, this study investigates the prognostic impact of NED in mCRPC patients treated with ARPIs. Methods: We retrospectively analyzed 327 mCRPC patient data treated with Enzalutamide or Abiraterone in the first and second or successive lines of treatment. NED was assessed using prostate biopsy samples through immunohistochemical staining. Results: NED was confirmed in 32/327 (9.8%) mCRPC patients. In the overall population, mCRPC with NED showed worse PFS (4.38 vs. 11.48 months HR 2.505 [1.71–3.68] p < 0.05), disease control rate (DCR), and PSA response. In the first line setting, mCRPC with NED demonstrated worse PFS (8.5 vs. 14.9 months HR 2.13 [1.18–3.88], p < 0.05). Similarly, in the second or successive lines, mCRPC with NED showed worse PFS (4.0 vs. 7.5 months HR 2.43 [1.45–4.05] p < 0.05), DCR, PSA response and OS (12.53 vs. 18.03 months HR 1.86 [1.12–3.10] p < 0.05). The adverse impact of NED on PFS was consistence across all subgroups; we also noted a trend of worse PFS in patients with high vs. low NED. Conclusions: In our study, mCRPC with NED treated with Enzalutamide or Abiraterone showed worse clinical outcomes. NED assessment should be considered to optimize treatment decisions in the mCRPC setting.
- Published
- 2024
- Full Text
- View/download PDF
4. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
- Author
-
Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello
- Published
- 2024
- Full Text
- View/download PDF
5. Liquid Biopsy in Advanced Colorectal Cancer: Clinical Applications of Different Analytes
- Author
-
Marco Donatello Delcuratolo, Andrea Modrego-Sánchez, Maristella Bungaro, Beatriz Antón-Pascual, Santiago Teran, Valentina Dipace, Silvia Novello, Rocio Garcia-Carbonero, Francesco Passiglia, and Cristina Graválos-Castro
- Subjects
colorectal cancer ,metastatic ,liquid biopsy ,exosomes ,circulating tumor cells ,circulating tumor DNA ,Pathology ,RB1-214 - Abstract
Colorectal cancer is one of the most prevalent cancers nowadays. In the metastatic setting, diagnosis and treatment have relied on tumor tissue analysis. However, the different limitations of this approach have recently opened the door to the introduction of liquid biopsy in the clinical setting. Liquid biopsy provides real-time information about the tumor and its heterogeneity in a simple, non-invasive, and repeatable way. There are several analytes that can be sought: exosomes, circulating tumor cells, and circulating tumor DNA, showing promising results in the areas of early detection, minimal residual disease, prognosis, or response to treatment. Here, we review the clinical applications of liquid biopsy in advanced colorectal cancer patients, focusing on metastatic diagnosis, prognostic assessment, drug sensitivity, treatment response, and acquired resistance monitoring.
- Published
- 2023
- Full Text
- View/download PDF
6. Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway
- Author
-
Marinello, Jessica, Arleo, Andrea, Russo, Marco, Delcuratolo, Maria, Ciccarelli, Francesca, Pommier, Yves, and Capranico, Giovanni
- Published
- 2022
- Full Text
- View/download PDF
7. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
- Author
-
Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, Tiseo, Marcello, Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello
- Abstract
Purpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. Methods: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs). Results: 1068 patients were enrolled at the time of data cut-off (January 31st, 2023), and 812 (76.0%) belonged to the retrospective cohort. Median age was 66 years (27−85), ECOG PS was ≥ 2 in 91 (8.6%) patients; 254 (23.8%) patients had brain metastases at baseline; 38 (3.6%) patients had tumor with PD-L1 expression ≥ 50%. After a median follow-up of 17.0 months (95% CI, 16.1–17.9), median OS was 16.1 months (95% CI, 14.4–18.8) and PFS was 9.9 months (95% CI, 8.8–11.2). Median DoR (n = 493) was 14.7 months (95% CI, 13.6–17.1). ORR was 43.4% (95% CI, 40.4–46.4). Any-grade AEs occurred in 636 (59.6%) patients and grade ≥ 3 in 253 (23.7%) patients. Most common grade ≥ 3 AEs were neutropenia (6.3%) and anemia (6.3%). Conclusions: First-line chemo-immunotherapy was effective and tolerable in this large, real-world Italian study of patients with advanced non-squamous NSCLC. Our results were in line with the KEYNOTE-189 registration study, also considering the low number of PD-L1 ≥ 50% patients included in our study.
- Published
- 2024
8. Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors
- Author
-
Delcuratolo, Marco Donatello, Tucci, Marcello, Turco, Fabio, Di Stefano, Rosario Francesco, Ungaro, Antonio, Audisio, Marco, Samuelly, Alessandro, Brusa, Federica, Audisio, Alessandro, Di Maio, Massimo, Scagliotti, Giorgio Vittorio, and Buttigliero, Consuelo
- Published
- 2023
- Full Text
- View/download PDF
9. Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
- Author
-
Fabio Turco, Marcello Tucci, Marco Donatello Delcuratolo, Rosario Francesco Di Stefano, Chiara Pisano, Alessandro Audisio, Marco Audisio, Antonio Ungaro, Cinzia Ortega, Massimo Di Maio, Giorgio Vittorio Scagliotti, and Consuelo Buttigliero
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2022
- Full Text
- View/download PDF
10. Risk Factors and Cellular Differences in Heart Failure: The Key Role of Sex Hormones
- Author
-
Elvira Delcuratolo, Alberto Palazzuoli, Francesca Coppi, Anna Vittoria Mattioli, Paolo Severino, Francesco Tramonte, and Francesco Fedele
- Subjects
heart failure phenotypes ,sex differences ,sex hormones ,biomarkers ,risk factors ,Biology (General) ,QH301-705.5 - Abstract
Patients with heart failure are conventionally stratified into phenotypic groups based on their ejection fraction. The aim of this stratification is to improve disease management with a more targeted therapeutic approach. A further subdivision based on patient gender is justified. It is recognized that women are underrepresented in randomized controlled clinical trials, resulting in limited clinical and molecular differentiation between males and females. However, many observational studies show that the onset, development, and clinical course of the disease may substantially differ between the two sexes. According to the emerging concept of precision medicine, investigators should further explore the mechanisms responsible for the onset of heart failure due to sex differences. Indeed, the synergistic or opposing effects of sex hormones on the cardiovascular system and underlying heart failure mechanisms have not yet been clarified. Sex hormones, risk factors impact, and cardiovascular adaptations may be relevant for a better understanding of the intrinsic pathophysiological mechanisms in the two sexes. Despite the differences, treatment for HF is similar across the whole population, regardless of sex and gender. In our review, we describe the main differences in terms of cardiovascular dysfunction, risk factors, and cellular signaling modifications related to the hormonal pattern.
- Published
- 2023
- Full Text
- View/download PDF
11. Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis.
- Author
-
Farinea, Giovanni, Calabrese, Mariangela, Carfì, Federica, Saporita, Isabella, Poletto, Stefano, Delcuratolo, Marco Donatello, Turco, Fabio, Audisio, Marco, Di Stefano, Francesco Rosario, Tucci, Marcello, and Buttigliero, Consuelo
- Subjects
CASTRATION-resistant prostate cancer ,ANDROGEN receptors ,IMMUNOSTAINING ,PROSTATE biopsy ,NEUROENDOCRINE tumors - Abstract
Neuroendocrine differentiation (NED) represents a possible androgen receptor pathway inhibitors (ARPI) resistance mechanism in metastatic castration resistance prostate cancer (mCRPC). As mCRPC with NED has been excluded from clinical trials evaluating ARPI efficacy, this study investigates the prognostic impact of NED in mCRPC patients treated with ARPIs. Methods: We retrospectively analyzed 327 mCRPC patient data treated with Enzalutamide or Abiraterone in the first and second or successive lines of treatment. NED was assessed using prostate biopsy samples through immunohistochemical staining. Results: NED was confirmed in 32/327 (9.8%) mCRPC patients. In the overall population, mCRPC with NED showed worse PFS (4.38 vs. 11.48 months HR 2.505 [1.71–3.68] p < 0.05), disease control rate (DCR), and PSA response. In the first line setting, mCRPC with NED demonstrated worse PFS (8.5 vs. 14.9 months HR 2.13 [1.18–3.88], p < 0.05). Similarly, in the second or successive lines, mCRPC with NED showed worse PFS (4.0 vs. 7.5 months HR 2.43 [1.45–4.05] p < 0.05), DCR, PSA response and OS (12.53 vs. 18.03 months HR 1.86 [1.12–3.10] p < 0.05). The adverse impact of NED on PFS was consistence across all subgroups; we also noted a trend of worse PFS in patients with high vs. low NED. Conclusions: In our study, mCRPC with NED treated with Enzalutamide or Abiraterone showed worse clinical outcomes. NED assessment should be considered to optimize treatment decisions in the mCRPC setting. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
- Author
-
Maria Rescigno, Chiara Agrati, Carlo Salvarani, Diana Giannarelli, Massimo Costantini, Alberto Mantovani, Raffaella Massafra, Pier Luigi Zinzani, Aldo Morrone, Stefania Notari, Giulia Matusali, Giuseppe Lauria Pinter, Antonio Uccelli, Gennaro Ciliberto, Fausto Baldanti, Franco Locatelli, Nicola Silvestris, Valentina Sinno, Elena Turola, Maria Teresa Lupo-Stanghellini, Giovanni Apolone, the VAX4FRAIL study Group, Fabio Ciceri, Massimo Tommasino, Giuseppe Lauri Pinter, Paolo Corradini, Daniela Fenoglio, Roberta Mortarini, Laura Conti, Chiara Mandoj, Michela Lizier, Stefania Croci, Vito Garrisi, Fulvio Baggi, Tiziana Lazzarotto, Francesca Bonifazi, Concetta Quintarelli, Rita Carsetti, Enrico Girardi, Aurora Bettini, Veronica Bordoni, Concetta Castilletti, Eleonora Cimini, Rita Casetti, Francesca Colavita, Flavia Cristofanelli, Massimo Francalancia, Simona Gili, Delia Goletti, Giulia Gramigna, Germana Grassi, Daniele Lapa, Sara Leone, Davide Mariotti, Silvia Meschi, Enzo Puro, Marika Rubino, Alessandra Sacchi, Eleonora Tartaglia, Silvia Damian, Vincenzo Marasco, Filippo de Braud, Maria Teresa Lupo Stanghellini, Lorenzo Dagna, Francesca Ogliari, Massimo Filippi, Alessandro Bruno, Gloria Catalano, Rosamaria Nitti, Andrea Mengarelli, Francesco Marchesi, Giancarlo Paoletti e Gabriele Minuti, Elena Papa, Elena Azzolini, Luca Germagnoli, Carlo Selmi, Maria De Santis, Carmelo Carlo-Stella, Alexia Bertuzzi, Francesca Motta, Angela Ceribelli, Chiara Miggiano, Giulia Fornasa, Sara Monti, Carlo Maurizio Montecucco, Dario Graceffa, Maria Grazia Catanoso, Monica Guberti, Carmine Pinto, Francesco Merli, Franco Valzania, Rosa Divella, Antonio Tufaro, Sabina Delcuratolo, Mariana Miano, Carlo Antozzi, Silvia Bonanno Rita Frangiamore, Lorenzo Maggi, Paolo Pronzato, Matilde Inglese, Carlo Genova, Caterina Lapucci, Alice Laroni, Ilaria Poiré, Marco Fusconi, Vittorio Stefoni, Maria Abbondanza Pantaleo, Serena Di Cosimo, Iolanda Pulice, Roberta Mennitto Fondazione, Stefania Trinca, Giulia Piaggio, Chiara Pozzi, Irene Cassaniti, Alessandro Barberini, Rinaldi Elena, Federica Bortone, Maria Giovanna Dal Bello, and Silvia Corazza
- Subjects
SARS-CoV-2 mRNA vaccine ,humoral response ,T cell response ,immunocompromised patients ,Omicron neutralization ,cross immunity ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionImmunocompromised patients have been shown to have an impaired immune response to COVID-19 vaccines.MethodsHere we compared the B-cell, T-cell and neutralizing antibody response to WT and Omicron BA.2 SARS-CoV-2 virus after the fourth dose of mRNA COVID-19 vaccines in patients with hematological malignancies (HM, n=71), solid tumors (ST, n=39) and immune-rheumatological (IR, n=25) diseases. The humoral and T-cell responses to SARS-CoV-2 vaccination were analyzed by quantifying the anti-RBD antibodies, their neutralization activity and the IFN-γ released after spike specific stimulation.ResultsWe show that the T-cell response is similarly boosted by the fourth dose across the different subgroups, while the antibody response is improved only in patients not receiving B-cell targeted therapies, independent on the pathology. However, 9% of patients with anti-RBD antibodies did not have neutralizing antibodies to either virus variants, while an additional 5.7% did not have neutralizing antibodies to Omicron BA.2, making these patients particularly vulnerable to SARS-CoV-2 infection. The increment of neutralizing antibodies was very similar towards Omicron BA.2 and WT virus after the third or fourth dose of vaccine, suggesting that there is no preferential skewing towards either virus variant with the booster dose. The only limited step is the amount of antibodies that are elicited after vaccination, thus increasing the probability of developing neutralizing antibodies to both variants of virus.DiscussionThese data support the recommendation of additional booster doses in frail patients to enhance the development of a B-cell response directed against Omicron and/or to enhance the T-cell response in patients treated with anti-CD20.
- Published
- 2023
- Full Text
- View/download PDF
13. Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study
- Author
-
Serena Di Cosimo, Maria Teresa Lupo-Stanghellini, Massimo Costantini, Renato Mantegazza, Fabio Ciceri, Carlo Salvarani, Pier Luigi Zinzani, Alberto Mantovani, Gennaro Ciliberto, Antonio Uccelli, Fausto Baldanti, Giovanni Apolone, Sabina Delcuratolo, Aldo Morrone, Franco Locatelli, Chiara Agrati, and Nicola Silvestris
- Subjects
COVID – 19 ,vaccination ,frail adults ,adverse (side) effects ,safety ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
ImportanceDespite people with impaired immune competence due to an underlying disease or ongoing therapy, hereinafter frail patients, are (likely to be) the first to be vaccinated, they were usually excluded from clinical trials.ObjectiveTo report adverse reactions of frail patients after receipt of the third dose (booster) administered after completion of a two-dose mRNA vaccination and to compare with those reported after the receipt of the first two doses.DesignA multicenter, observational, prospective study aimed at evaluating both the safety profile and the immune response of Pfizer-BioNTech or Moderna vaccines in frail patients.SettingNational Project on Vaccines, COVID-19 and Frail Patients (VAX4FRAIL)ParticipantsPeople consenting and included in the VAX4FRAIL trial.ExposureA series of three doses of COVID-19 mRNA vaccination from the same manufacturer.Main outcome(s) and measure(s)Evaluation of a self-assessment questionnaire addressing a predefined list of eight symptoms on a five-item Likert scale. Symptoms were classified as severe if the patient rated them as severe or overwhelming.ResultsAmong 320 VAX4FRAIL participants diagnosed/treated for hematological malignancies (N=105; 32.8%), solid tumors (N=48; 15.0%), immune-rheumatological diseases (N=60; 18.8%), neurological diseases (N=107; 33.4%), and receiving the booster dose, 70.3% reported at least one loco-regional or systemic reactions. Adverse events were mostly mild or moderate, none being life-threatening. Only six of the 320 (1.9%) patients had their treatment postponed due to the vaccine. The safety profile of the booster compared to previously administered two doses showed a stable prevalence of patients with one or more adverse events (73.5%, 79.7% and 73.9% respectively), and a slightly increment of patients with one or more severe adverse events (13.4%, 13.9% and 19.2% respectively).Conclusions and relevanceThe booster of the mRNA COVID-19 vaccine was safely administered in the largest prospective cohort of frail patients reported so far. VAX4FRAIL will continue to monitor the safety of additional vaccine doses, especially systemic adverse events that can be easily prevented to avoid interruption of continuity of care.Clinical trial registrationhttps://clinicaltrials.gov/ct2/show/NCT04848493, identifier NCT04848493.
- Published
- 2022
- Full Text
- View/download PDF
14. Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era
- Author
-
Passiglia, Francesco, Leone, Gianmarco, Olmetto, Emanuela, Delcuratolo, Marco Donatello, Tabbò, Fabrizio, Reale, Maria Lucia, Bertaglia, Valentina, Consito, Lorena, Bironzo, Paolo, Capelletto, Enrica, and Novello, Silvia
- Published
- 2021
- Full Text
- View/download PDF
15. Commento agli artt. 67-bis, 67-ter, 69.1 e 69.2 t.u.b.
- Author
-
Costa, C, Mirone, A, de Luca, N, Delcuratolo, L, Nuzzo, G, Costa, C, Mirone, A, de Luca, N, Delcuratolo, L, and Nuzzo, G
- Published
- 2024
16. Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma
- Author
-
Samuelly, Alessandro, primary, Di Stefano, Rosario Francesco, additional, Turco, Fabio, additional, Delcuratolo, Marco Donatello, additional, Pisano, Chiara, additional, Saporita, Isabella, additional, Calabrese, Mariangela, additional, Carfì, Federica Maria, additional, Tucci, Marcello, additional, and Buttigliero, Consuelo, additional
- Published
- 2024
- Full Text
- View/download PDF
17. Risk Factors and Cellular Differences in Heart Failure: The Key Role of Sex Hormones
- Author
-
Delcuratolo, Elvira, primary, Palazzuoli, Alberto, additional, Coppi, Francesca, additional, Mattioli, Anna Vittoria, additional, Severino, Paolo, additional, Tramonte, Francesco, additional, and Fedele, Francesco, additional
- Published
- 2023
- Full Text
- View/download PDF
18. ACUTE HF score predicts in-hospital mortality in patients with acute heart failure
- Author
-
Pastore, M C, primary, Mandoli, G E, additional, Campora, A, additional, Renzelli, A, additional, Olivoni, G, additional, Toscano, M, additional, Pavoncelli, S, additional, Delcuratolo, E, additional, Lambardi, M, additional, Morrone, F, additional, Cavigli, L, additional, Focardi, M, additional, D'ascenzi, F, additional, Valente, S, additional, and Cameli, M, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
- Author
-
Irene Persano, Massimiliano Cani, Benedetta Del Rio, Giorgia Ferrari, Edoardo Garbo, Elena Parlagreco, Chiara Pisano, Valeria Cetoretta, Marco Donatello Delcuratolo, Fabio Turco, Alessandro Audisio, Cristina Cecchi, Gianmarco Leone, Valerio Maria Napoli, Valentina Bertaglia, Valentina Bianco, Enrica Capelletto, Carmen D’Amiano, Massimo Di Maio, Martina Gianetta, Silvia Novello, Francesco Passiglia, Giorgio Vittorio Scagliotti, and Paolo Bironzo
- Subjects
COVID-19 pandemic ,SARS-CoV-2 infection ,prevention strategies ,COVID-19 vaccination ,cancer patients ,patients reported outcomes ,Biology (General) ,QH301-705.5 - Abstract
Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to participate in our vaccination campaign received BNT162b2 and were included in the descriptive analysis. An anonymous questionnaire investigating the occurrence of SEs/AEs and PROs was administered to the study population 21 days after the first dose. Pearson’s chi-squared test was used to estimate the risk of experiencing SEs/AEs according to selected variables. A total of 997 patients were included in the study: 62.0% had stage IV cancer, and 68.8% were receiving an active treatment, of whom 15.9% were receiving immunotherapy. SEs/AEs were recorded in 37.1% of cases after the first dose and in 48.5% of cases after the second dose. The most common SEs were muscle pain/local rash (27.9% and 28%, after the first and second dose, respectively). Patients older than 70 years showed lower risk of SEs/AEs, while women showed a higher risk. Before receiving the vaccine, 18.2% of patients felt fearful and/or insecure about the vaccination. After the first dose, 57.5% of patients changed their feelings positively. Our data support the short-term safety of BNT162b2 in CPs, regardless of disease stage and concurrent treatments. Overall, the vaccination showed a positive impact on quality of life.
- Published
- 2023
- Full Text
- View/download PDF
20. Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
- Author
-
Marco Audisio, Consuelo Buttigliero, Fabio Turco, Marco Donatello Delcuratolo, Chiara Pisano, Elena Parlagreco, Rosario Francesco Di Stefano, Lavinia Di Prima, Veronica Crespi, Giovanni Farinea, Massimiliano Cani, and Marcello Tucci
- Subjects
urothelial cancer ,immunotherapy ,FGFR inhibitors ,enfortumab vedotin ,Cytology ,QH573-671 - Abstract
Urothelial cancer is a lethal malignancy characterized by a wide diffusion in Western countries due to a larger exposure to known risk factors, such as aromatic amines, tobacco smoke and benzene [...]
- Published
- 2022
- Full Text
- View/download PDF
21. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside
- Author
-
Antonio Ungaro, Marcello Tucci, Alessandro Audisio, Lavinia Di Prima, Chiara Pisano, Fabio Turco, Marco Donatello Delcuratolo, Massimo Di Maio, Giorgio Vittorio Scagliotti, and Consuelo Buttigliero
- Subjects
urothelial carcinoma ,antibody-drug conjugates ,ADC ,Enfortumab vedotin ,ADC resistance mechanism ,Cytology ,QH573-671 - Abstract
Significant progress has been achieved over the last decades in understanding the biology and mechanisms of tumor progression in urothelial carcinoma (UC). Although the therapeutic landscape has dramatically changed in recent years with the introduction of immune checkpoint inhibitors, advanced UC is still associated with rapidly progressing disease and poor survival. The increasing knowledge of the pathogenesis and molecular pathways underlying cancer development and progression is leading the introduction of target therapies, such as the recently approved FGFR inhibitor Erdafitinib, or the anti-nectin 4 antibody drug-conjugate Enfortumab vedotin. Antibody drug conjugates represent an innovative therapeutic approach that allows the combination of a tar get-specific monoclonal antibody covalently conjugated via a linker to a cytotoxic agent (payload). UC is a perfect candidate for this therapeutic approach since it is particularly enriched in antigen expression on its surface and each specific antigen can represent a potential therapeutic target. In this review we summarize the mechanism of action of ADCs, their applications in localized and metastatic UC, the main mechanisms of resistance, and future perspectives for their use in clinical practice.
- Published
- 2022
- Full Text
- View/download PDF
22. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
- Author
-
Francesca Foschini, Fabiana Napolitano, Alberto Servetto, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Antonio Santaniello, Pietro De Placido, Priscilla Cascetta, Giovanni Butturini, Isabella Frigerio, Paolo Regi, Nicola Silvestris, Sabina Delcuratolo, Enrico Vasile, Caterina Vivaldi, Cataldo Bianco, Sabino De Placido, Luigi Formisano, and Roberto Bianco
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death. In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy regimens are considered the standard of care. However, the optimal sequence of these regimens is unclear. Methods: This retrospective study initially evaluated 186 patients with locally advanced/metastatic pancreatic cancer at three Italian institutions between February 2013 and October 2019. All patients had progressed after receiving gemcitabine-based first-line chemotherapy and were subsequently offered second-line FOLFIRINOX, FOLFOX-6, or FOLFIRI treatment. This study evaluated progression-free survival (PFS), overall survival from the start of second-line treatment (OS2), overall survival from the start of first-line treatment (OS1), and safety outcomes. Results: A total of 77 patients received ⩾4 cycles of second-line chemotherapy and were considered eligible: 15 patients received FOLFIRINOX, 32 patients received FOLFOX-6, and 30 patients received FOLFIRI. The FOLFIRINOX group had median PFS of 26.29 weeks and median OS2 of 47.86 weeks, while the FOLFIRI group had median PFS of 10.57 weeks and median OS2 of 25.00 weeks ( p = 0.038). No significant differences were observed between the FOLFIRINOX and FOLFOX-6 groups in terms of PFS (26.29 weeks versus 23.07 weeks) or OS2 (47.86 weeks versus 42.00 weeks). The most common grade 3–4 toxicities were anemia, neutropenia, and thrombocytopenia, which occurred more frequently in the FOLFIRINOX and FOLFOX-6 groups. Conclusion: Relative to the FOLFIRI regimen, the FOLFIRINOX regimen had a favorable toxicity profile and better survival outcomes. No significant differences were observed relative to the FOLFOX-6 regimen.
- Published
- 2020
- Full Text
- View/download PDF
23. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
- Author
-
Francesco Caputo, Vincenzo Dadduzio, Francesco Tovoli, Giulia Bertolini, Giuseppe Cabibbo, Krisida Cerma, Caterina Vivaldi, Luca Faloppi, Mario Domenico Rizzato, Fabio Piscaglia, Ciro Celsa, Lorenzo Fornaro, Giorgia Marisi, Fabio Conti, Nicola Silvestris, Marianna Silletta, Sara Lonardi, Alessandro Granito, Caterina Stornello, Valentina Massa, Giorgio Astara, Sabina Delcuratolo, Stefano Cascinu, Mario Scartozzi, and Andrea Casadei-Gardini
- Subjects
Medicine ,Science - Abstract
BACKGROUND AND AIMS:The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. METHODS:This multicentric study included a training cohort of 194 HCC patients and three external validation cohorts of 129, 76 and 265 HCC patients treated with Sorafenib, respectively. The PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Univariate and multivariate analyses were performed to investigate the association between the covariates and the overall survival (OS). RESULTS:A PNI cut-off value of 31.3 was established using the ROC analysis. In the training cohort, the median OS was 14.8 months (95% CI 12-76.3) and 6.8 months (95% CI 2.7-24.6) for patients with a high (>31.3) and low ( 70 years (p< 0.0038) were independent prognostic factors for OS. By performing the same multivariate analysis of the training cohort, the PNI 31.3 was found to be an independent prognostic factor for predicting OS in all the three validation cohorts. CONCLUSIONS:PNI represents a prognostic tool in advanced HCC treated with first-line Sorafenib. It is readily available and low-cost, and it could be implemented in clinical practice in patients with HCC.
- Published
- 2020
- Full Text
- View/download PDF
24. Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
- Author
-
Antonella Argentiero, Angela Calabrese, Angela Monica Sciacovelli, Sabina Delcuratolo, Antonio Giovanni Solimando, and Oronzo Brunetti
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and short survival. Today, the use of new polytherapeutic regimens increases clinical outcome of these patients opening new clinical scenario. A crucial issue related to the actual improvement achieved with these new regimens is represented by the occasional possibility to observe a radiological complete response of metastatic lesions in patients with synchronous primary tumor. What could be the best therapeutic management of these patients? Could surgery represent an indication? Herein, we reported a case of a patient with PDAC of the head with multiple liver metastases, who underwent first-line chemotherapy with mFOLFIRINOX. After 10 cycles, he achieved a complete radiological response of liver metastases and a partial response of pancreatic lesion. A duodenocephalopancreasectomy was performed. Due to liver a lung metastases after 8 months from surgery, a second-line therapy was started with a disease-free survival and overall survival of 8 months and 45 months, respectively. Improvement in the molecular characterization of PDAC could help in the selection of patients suitable for multimodal treatments. This trial is registered with NCT02892305 and NCT00855634.
- Published
- 2020
- Full Text
- View/download PDF
25. New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond
- Author
-
Alessandro Audisio, Consuelo Buttigliero, Marco Donatello Delcuratolo, Elena Parlagreco, Marco Audisio, Antonio Ungaro, Rosario Francesco Di Stefano, Lavinia Di Prima, Fabio Turco, and Marcello Tucci
- Subjects
non-muscle-invasive bladder cancer ,BGC-unresponsive ,immunotherapy ,immune-checkpoint inhibitors ,pembrolizumab ,Cytology ,QH573-671 - Abstract
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high rate of cure, but also by a non-negligible probability of recurrence and risk progression to muscle-invasive disease. NMIBC management requires a proper local resection and staging, followed by a risk-based treatment with intravesical agents. For many years, the current gold standard treatment for patients with intermediate or high-risk disease is transurethral resection of the bladder (TURB) followed by intravesical bacillus Calmette–Guérin (BCG) instillations. Unfortunately, in about half of high-risk patients, intravesical BCG treatment fails and NMIBC persists or recurs early. While radical cystectomy remains the gold standard for these patients, new therapeutic targets are being individuated and studied. Radical cystectomy in fact can provide an excellent long-term disease control, but can deeply interfere with quality of life. In particular, the enhanced immune checkpoints expression shown in BCG-unresponsive patients and the activity of immune checkpoints inhibitors (ICIs) in advanced bladder cancer provided the rationale for testing ICIs in NMIBC. Recently, pembrolizumab has shown promising activity in BCG-unresponsive NMIBC patients, obtaining FDA approval. Meanwhile multiple novel drugs with alternative mechanisms of action have proven to be safe and effective in NMIBC treatment and others are under investigation. The aim of this review is to analyse and describe the clinical activity of new emerging drugs in BCG-unresponsive NMIBC focusing on immunotherapy results.
- Published
- 2022
- Full Text
- View/download PDF
26. Liquid Biopsy in Advanced Colorectal Cancer: Clinical Applications of Different Analytes
- Author
-
Delcuratolo, Marco Donatello, primary, Modrego-Sánchez, Andrea, additional, Bungaro, Maristella, additional, Antón-Pascual, Beatriz, additional, Teran, Santiago, additional, Dipace, Valentina, additional, Novello, Silvia, additional, Garcia-Carbonero, Rocio, additional, Passiglia, Francesco, additional, and Graválos-Castro, Cristina, additional
- Published
- 2023
- Full Text
- View/download PDF
27. Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
- Author
-
Persano, Irene, primary, Cani, Massimiliano, additional, Del Rio, Benedetta, additional, Ferrari, Giorgia, additional, Garbo, Edoardo, additional, Parlagreco, Elena, additional, Pisano, Chiara, additional, Cetoretta, Valeria, additional, Delcuratolo, Marco Donatello, additional, Turco, Fabio, additional, Audisio, Alessandro, additional, Cecchi, Cristina, additional, Leone, Gianmarco, additional, Napoli, Valerio Maria, additional, Bertaglia, Valentina, additional, Bianco, Valentina, additional, Capelletto, Enrica, additional, D’Amiano, Carmen, additional, Di Maio, Massimo, additional, Gianetta, Martina, additional, Novello, Silvia, additional, Passiglia, Francesco, additional, Scagliotti, Giorgio Vittorio, additional, and Bironzo, Paolo, additional
- Published
- 2023
- Full Text
- View/download PDF
28. PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study
- Author
-
Nicola Silvestris, Fulvia Colonna, Antonio Giovanni Solimando, Sabina Delcuratolo, Concetta Saponaro, Aldo Scarpa, Livia Fucci, Margherita Sonnessa, Claudio Luchini, Floriana Nappo, Antonella Argentiero, Sara Lonardi, Matteo Fassan, and Oronzo Brunetti
- Subjects
PD-L1 ,Notch ,Clinical Biochemistry ,Pilot Projects ,Biology ,Immunofluorescence ,B7-H1 Antigen ,Immunophenotyping ,Immune system ,Pancreatic cancer ,Drug Discovery ,Biomarkers, Tumor ,Tumor Microenvironment ,medicine ,Humans ,Receptor, Notch1 ,Sarcomatoid carcinoma ,Receptor, Notch3 ,rare pancreatic carcinoma ,Retrospective Studies ,Pharmacology ,Tumor microenvironment ,pancreatic sarcomatoid carcinoma ,medicine.diagnostic_test ,pd-l1 ,medicine.disease ,Pancreatic Neoplasms ,Cancer cell ,biology.protein ,Cancer research ,Molecular Medicine - Abstract
Background The improved immunological understanding revealed the tumor microenvironment as an appealing driver to restore the immune response against cancer cells resulting in a paradigm shift in the oncology field. However, the complexity of the tumor milieu suggests a role of several pathways linking in immunomodulation mechanisms. Pancreatic cancer represents a model of the intricate relationship between malignant cells and their surrounding neighborhood. Research design and methods In this study we analyzed, retrospectively, 6 cases of rare pancreatic sarcomatoid carcinoma (PSC) and evaluated the expression of PD-L1 and Notch, aiming to explore new attributes in immunophenotype. Results PD-L1 CPS≥1% was common in PSCs (83%) with half samples expressing PD-L1 CPS≥50%. Notch1 and Notch3 expression resulted positive demonstrating a high IRS range of expression. A direct significant correlation between PD-L1 and Nocth3 overexpression (r=0.7; p=0.036) has been observed. Moreover, immunofluorescence studies revealed a co-localization of Notch3 and PD-L1 when both proteins were over-expressed within cytoplasmic or membranous compartments of the same cells. Conclusions Our data identify a unique biological characterization of this rare pancreatic histotype. These findings provide a rationale for future studies evaluating the potential crosstalk between PD-L1/PD-1 axis and Notch pathways and prompting the development of novel therapeutics strategy.
- Published
- 2021
29. Black Hairy Tongue After Immune Checkpoint Inhibitors in NSCLC: A Case Report and Review of the Literature
- Author
-
Annapaola Mariniello, Simona Carnio, Cristina Cecchi, Silvia Novello, and Marco Donatello Delcuratolo
- Subjects
Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Population ,Context (language use) ,Pembrolizumab ,03 medical and health sciences ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Mucositis ,Humans ,Adverse effect ,education ,Immune Checkpoint Inhibitors ,Aged ,education.field_of_study ,business.industry ,Cancer ,medicine.disease ,Dysgeusia ,030104 developmental biology ,Tongue, Hairy ,030220 oncology & carcinogenesis ,Black hairy tongue ,medicine.symptom ,business - Abstract
Clinical Practice Points • Immune checkpoint inhibitors (ICIs) are associated with the development of unique immune-related adverse events (irAEs), which emerged primarily during post-marketing surveillance. Oral irAEs have already been reported, with the most common manifestations being mucositis and xerostomia. It has been suggested that a T-cell activation, similar to that observed in autoimmune conditions, may play a role. • Here, we report a case of black hairy tongue (BHT) in a patient receiving first-line pembrolizumab for advanced non–small-cell lung cancer (NSCLC). Although the BHT was symptomatic for burning mouth and dysgeusia, ICI use was continued due to its clinical and radiological benefit, which persisted for a long time. • BHT is characterized by hypertrophy and lengthening of the filiform papillae. Despite being a rare benign condition, it can often result in a significant burden on quality of life. • Many predisposing factors have been described, and cancer patients represent a population particularly at risk. Based on the temporal association and excluding possible alternative causes, we proposed that, in our patient, BHT was likely ICI related through the development of xerostomia, which represents a key factor in BHT pathogenesis. • To the best of our knowledge, this is the first report of BHT after ICI use, suggesting that it may represent an atypical oral irAE. To date, the oral irAEs have not been well explored, and further studies are needed to elucidate the underlying mechanisms and possible associations with anti-tumor responses, with significant implications on prognosis and quality of life. In the present context, our case emphasizes the need to remain vigilant for atypical and new irAEs.
- Published
- 2021
30. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
- Author
-
Antonio Gnoni, Antonella Licchetta, Riccardo Memeo, Antonella Argentiero, Antonio G. Solimando, Vito Longo, Sabina Delcuratolo, and Oronzo Brunetti
- Subjects
braf ,hepatocellular carcinoma ,liver microenvironment ,mapk pathway ,mek ,sorafenib ,tki ,Medicine (General) ,R5-920 - Abstract
The few therapeutic strategies for advance hepatocellular carcinoma (HCC) on poor knowledge of its biology. For several years, sorafenib, a tyrosine kinase inhibitors (TKI) inhibitor, has been the approved treatment option, to date, for advanced HCC patients. Its activity is the inhibition of the retrovirus-associated DNA sequences protein (RAS)/Rapidly Accelerated Fibrosarcoma protein (RAF)/mitogen-activated and extracellular-signal regulated kinase (MEK)/extracellular-signal regulated kinases (ERK) signaling pathway. However, the efficacy of sorafenib is limited by the development of drug resistance, and the major neuronal isoform of RAF, BRAF and MEK pathways play a critical and central role in HCC escape from TKIs activity. Advanced HCC patients with a BRAF mutation display a multifocal and/or more aggressive behavior with resistance to TKI. Moreover, also long non-coding RNA (lnc-RNA) have been studied in epigenetic studies for BRAF aggressiveness in HCC. So far, lnc-RNA of BRAF could be another mechanism of cancer proliferation and TKI escape in HCC and the inhibition could become a possible strategy treatment for HCC. Moreover, recent preclinical studies and clinical trials evidence that combined treatments, involving alternative pathways, have an important role of therapy for HCC and they could bypass resistance to the following TKIs: MEK, ERKs/ribosomal protein S6 kinase 2 (RSK2), and phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR). These initial data must be confirmed in clinical studies, which are currently ongoing. Translational research discoveries could create new strategies of targeted therapy combinations, including BRAF pathway, and they could eventually bring light in new treatment of HCC.
- Published
- 2019
- Full Text
- View/download PDF
31. Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study
- Author
-
Di Cosimo, Serena, primary, Lupo-Stanghellini, Maria Teresa, additional, Costantini, Massimo, additional, Mantegazza, Renato, additional, Ciceri, Fabio, additional, Salvarani, Carlo, additional, Zinzani, Pier Luigi, additional, Mantovani, Alberto, additional, Ciliberto, Gennaro, additional, Uccelli, Antonio, additional, Baldanti, Fausto, additional, Apolone, Giovanni, additional, Delcuratolo, Sabina, additional, Morrone, Aldo, additional, Locatelli, Franco, additional, Agrati, Chiara, additional, and Silvestris, Nicola, additional
- Published
- 2022
- Full Text
- View/download PDF
32. Emerging insights of drug resistance in metastatic castration resistant prostate cancer.
- Author
-
Ungaro, A., primary, Parlagreco, E., additional, Di Stefano, R.F., additional, Audisio, M., additional, Delcuratolo, M.D., additional, Di Prima, L., additional, Audisio, A., additional, Samuelly, A., additional, Tucci, M., additional, and Buttigliero, C., additional
- Published
- 2022
- Full Text
- View/download PDF
33. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
- Author
-
Oronzo Brunetti, Antonio Gnoni, Antonella Licchetta, Vito Longo, Angela Calabrese, Antonella Argentiero, Sabina Delcuratolo, Antonio Giovanni Solimando, Andrea Casadei-Gardini, and Nicola Silvestris
- Subjects
sorafenib ,hepatocellular carcinoma ,prognostic factors ,predictive factors ,Medicine (General) ,R5-920 - Abstract
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed similar results in terms of survival in a non-inferiority randomized trial study considering the same subset of patients. Unlike other targeted therapies, predictive and prognostic markers in HCC patients treated with sorafenib are lacking. Their identification could help clinicians in the daily management of these patients, mostly in light of the new therapeutic options available in the first.
- Published
- 2019
- Full Text
- View/download PDF
34. Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
- Author
-
Vito Longo, Oronzo Brunetti, Antonio Gnoni, Antonella Licchetta, Sabina Delcuratolo, Riccardo Memeo, Antonio Giovanni Solimando, and Antonella Argentiero
- Subjects
hepatocellular carcinoma ,immune checkpoint inhibitors ,hcc ,pembrolizumab ,nivolumab ,immune microenvironment ,targeted therapies ,Medicine (General) ,R5-920 - Abstract
Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading cause of cancer death worldwide. A total of 70−80% of patients are diagnosed at an advanced stage with a dismal prognosis. Sorafenib had been the standard care for almost a decade until 2018 when the Food and Drug Administration approved an alternative first-line agent namely lenvatinib. Cabozantinib, regorafenib, and ramucirumab also displayed promising results in second line settings. FOLFOX4, however, results in an alternative first-line treatment for the Chinese clinical oncology guidelines. Moreover, nivolumab and pembrolizumab, two therapeutics against the Programmed death (PD)-ligand 1 (PD-L1)/PD1 axis have been recently approved for subsequent-line therapy. However, similar to other solid tumors, the response rate of single agent targeting PD-L1/PD1 axis is low. Therefore, a lot of combinatory approaches are under investigation, including the combination of different immune checkpoint inhibitors (ICIs), the addition of ICIs after resection or during loco-regional therapy, ICIs in addition to kinase inhibitors, anti-angiogenic therapeutics, and others. This review focuses on the use of ICIs for the hepatocellular carcinoma with a careful assessment of new ICIs-based combinatory approaches.
- Published
- 2019
- Full Text
- View/download PDF
35. Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
- Author
-
Turco, Fabio, primary, Tucci, Marcello, additional, Delcuratolo, Marco Donatello, additional, Di Stefano, Rosario Francesco, additional, Pisano, Chiara, additional, Audisio, Alessandro, additional, Audisio, Marco, additional, Ungaro, Antonio, additional, Ortega, Cinzia, additional, Di Maio, Massimo, additional, Scagliotti, Giorgio Vittorio, additional, and Buttigliero, Consuelo, additional
- Published
- 2022
- Full Text
- View/download PDF
36. Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
- Author
-
Audisio, Marco, primary, Buttigliero, Consuelo, additional, Turco, Fabio, additional, Delcuratolo, Marco Donatello, additional, Pisano, Chiara, additional, Parlagreco, Elena, additional, Di Stefano, Rosario Francesco, additional, Di Prima, Lavinia, additional, Crespi, Veronica, additional, Farinea, Giovanni, additional, Cani, Massimiliano, additional, and Tucci, Marcello, additional
- Published
- 2022
- Full Text
- View/download PDF
37. Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives
- Author
-
Jessica Marinello, Maria Delcuratolo, and Giovanni Capranico
- Subjects
topoisomerase II ,anthracyclines ,DNA damage ,toxic effects ,immunogenic cell death ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Mammalian DNA topoisomerases II are targets of anticancer anthracyclines that act by stabilizing enzyme-DNA complexes wherein DNA strands are cut and covalently linked to the protein. This molecular mechanism is the molecular basis of anthracycline anticancer activity as well as the toxic effects such as cardiomyopathy and induction of secondary cancers. Even though anthracyclines have been used in the clinic for more than 50 years for solid and blood cancers, the search of breakthrough analogs has substantially failed. The recent developments of personalized medicine, availability of individual genomic information, and immune therapy are expected to change significantly human cancer therapy. Here, we discuss the knowledge of anthracyclines as Topoisomerase II poisons, their molecular and cellular effects and toxicity along with current efforts to improve the therapeutic index. Then, we discuss the contribution of the immune system in the anticancer activity of anthracyclines, and the need to increase our knowledge of molecular mechanisms connecting the drug targets to the immune stimulatory pathways in cancer cells. We propose that the complete definition of the molecular interaction of anthracyclines with the immune system may open up more effective and safer ways to treat patients with these drugs.
- Published
- 2018
- Full Text
- View/download PDF
38. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
- Author
-
Caputo F., Dadduzio V., Tovoli F., Bertolini G., Cabibbo G., Cerma K., Vivaldi C., Faloppi L., Rizzato M. D., Piscaglia F., Celsa C., Fornaro L., Marisi G., Conti F., Silvestris N., Silletta M., Lonardi S., Granito A., Stornello C., Massa V., Astara G., Delcuratolo S., Cascinu S., Scartozzi M., Casadei-Gardini A., Francesco Caputo,Vincenzo Dadduzio,Francesco Tovoli,Giulia Bertolini,Giuseppe Cabibbo,Krisida Cerma,Caterina Vivaldi,Luca Faloppi,Mario Domenico Rizzato,Fabio Piscaglia,Ciro Celsa,Lorenzo Fornaro,Giorgia Marisi,Fabio Conti,Nicola Silvestris,Marianna Silletta,Sara Lonardi,Alessandro Granito,Caterina Stornello,Valentina Massa,Giorgio Astara,Sabina Delcuratolo,Stefano Cascinu,Mario Scartozzi,Andrea Casadei-Gardini, Caputo, F., Dadduzio, V., Tovoli, F., Bertolini, G., Cabibbo, G., Cerma, K., Vivaldi, C., Faloppi, L., Rizzato, M. D., Piscaglia, F., Celsa, C., Fornaro, L., Marisi, G., Conti, F., Silvestris, N., Silletta, M., Lonardi, S., Granito, A., Stornello, C., Massa, V., Astara, G., Delcuratolo, S., Cascinu, S., Scartozzi, M., Casadei Gardini, A., Caputo F., Dadduzio V., Tovoli F., Bertolini G., Cabibbo G., Cerma K., Vivaldi C., Faloppi L., Rizzato M.D., Piscaglia F., Celsa C., Fornaro L., Marisi G., Conti F., Silvestris N., Silletta M., Lonardi S., Granito A., Stornello C., Massa V., Astara G., Delcuratolo S., Cascinu S., Scartozzi M., and Casadei-Gardini A.
- Subjects
RNA viruses ,Male ,Etiology ,Cancer Treatment ,Hepacivirus ,Kaplan-Meier Estimate ,Biochemistry ,Cohort Studies ,White Blood Cells ,Mathematical and Statistical Techniques ,Retrospective Studie ,Animal Cells ,Adult ,Aged ,Aged, 80 and over ,Antineoplastic Agents ,Carcinoma, Hepatocellular ,Female ,Humans ,Italy ,Liver Neoplasms ,Lymphocyte Count ,Middle Aged ,Prognosis ,Retrospective Studies ,Serum Albumin ,Sorafenib ,Nutrition Assessment ,Medicine and Health Sciences ,80 and over ,Lymphocytes ,Pathology and laboratory medicine ,Hepatitis C virus ,Liver Diseases ,Statistics ,Medical microbiology ,Oncology ,Liver Neoplasm ,Physical Sciences ,Viruses ,Medicine ,Pathogens ,Cellular Types ,Human ,Research Article ,Hepatitis B virus ,Immune Cells ,Science ,Immunology ,Gastroenterology and Hepatology ,Research and Analysis Methods ,Carcinomas ,Microbiology ,Albumins ,Gastrointestinal Tumors ,Statistical Methods ,Blood Cells ,Adult, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Hepatocellular, Cohort Studies, Female, Humans, Italy, Kaplan-Meier Estimate, Liver Neoplasms, Lymphocyte Count, Male, Middle Aged, Prognosis, Retrospective Studies, Serum Albumin, Sorafenib, Nutrition Assessment ,Biology and life sciences ,Flaviviruses ,Carcinoma ,Viral pathogens ,Organisms ,Cancers and Neoplasms ,Proteins ,Hepatocellular ,Hepatocellular Carcinoma ,Cell Biology ,prognostic nutritional index (PNI), hepatocellular carcinoma (HCC), sorafenib., survival, mRECIST ,Hepatitis viruses ,Microbial pathogens ,Multivariate Analysis ,Cohort Studie ,Mathematics - Abstract
Background and aims The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods This multicentric study included a training cohort of 194 HCC patients and three external validation cohorts of 129, 76 and 265 HCC patients treated with Sorafenib, respectively. The PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Univariate and multivariate analyses were performed to investigate the association between the covariates and the overall survival (OS). Results A PNI cut-off value of 31.3 was established using the ROC analysis. In the training cohort, the median OS was 14.8 months (95% CI 12–76.3) and 6.8 months (95% CI 2.7–24.6) for patients with a high (>31.3) and low ( 70 years (p< 0.0038) were independent prognostic factors for OS. By performing the same multivariate analysis of the training cohort, the PNI 31.3 was found to be an independent prognostic factor for predicting OS in all the three validation cohorts. Conclusions PNI represents a prognostic tool in advanced HCC treated with first-line Sorafenib. It is readily available and low-cost, and it could be implemented in clinical practice in patients with HCC.
- Published
- 2020
39. Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study
- Author
-
Di Cosimo, S., Lupo-Stanghellini, M. T., Costantini, M., Mantegazza, R., Ciceri, F., Salvarani, C., Zinzani, P. L., Mantovani, A., Ciliberto, G., Uccelli, A., Baldanti, F., Apolone, G., Delcuratolo, S., Morrone, A., Locatelli, Franco, Agrati, C., Silvestris, N., Locatelli F. (ORCID:0000-0002-7976-3654), Di Cosimo, S., Lupo-Stanghellini, M. T., Costantini, M., Mantegazza, R., Ciceri, F., Salvarani, C., Zinzani, P. L., Mantovani, A., Ciliberto, G., Uccelli, A., Baldanti, F., Apolone, G., Delcuratolo, S., Morrone, A., Locatelli, Franco, Agrati, C., Silvestris, N., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
Importance: Despite people with impaired immune competence due to an underlying disease or ongoing therapy, hereinafter frail patients, are (likely to be) the first to be vaccinated, they were usually excluded from clinical trials. Objective: To report adverse reactions of frail patients after receipt of the third dose (booster) administered after completion of a two-dose mRNA vaccination and to compare with those reported after the receipt of the first two doses. Design: A multicenter, observational, prospective study aimed at evaluating both the safety profile and the immune response of Pfizer-BioNTech or Moderna vaccines in frail patients. Setting: National Project on Vaccines, COVID-19 and Frail Patients (VAX4FRAIL) Participants: People consenting and included in the VAX4FRAIL trial. Exposure: A series of three doses of COVID-19 mRNA vaccination from the same manufacturer. Main outcome(s) and measure(s): Evaluation of a self-assessment questionnaire addressing a predefined list of eight symptoms on a five-item Likert scale. Symptoms were classified as severe if the patient rated them as severe or overwhelming. Results: Among 320 VAX4FRAIL participants diagnosed/treated for hematological malignancies (N=105; 32.8%), solid tumors (N=48; 15.0%), immune-rheumatological diseases (N=60; 18.8%), neurological diseases (N=107; 33.4%), and receiving the booster dose, 70.3% reported at least one loco-regional or systemic reactions. Adverse events were mostly mild or moderate, none being life-threatening. Only six of the 320 (1.9%) patients had their treatment postponed due to the vaccine. The safety profile of the booster compared to previously administered two doses showed a stable prevalence of patients with one or more adverse events (73.5%, 79.7% and 73.9% respectively), and a slightly increment of patients with one or more severe adverse events (13.4%, 13.9% and 19.2% respectively). Conclusions and relevance: The booster of the mRNA COVID-19 vaccine was safely adminis
- Published
- 2022
40. Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions
- Author
-
Sabina Delcuratolo, Michele Aieta, Daniele Santini, Patrizia Nardulli, Gianni Simone, Anna Elisabetta Brunetti, Amalia Azzariti, Aldo Scarpa, Antonio Gnoni, Antonella Licchetta, and Nicola Silvestris
- Subjects
carcinogenesis ,micro-RNAs ,oncogenes ,pancreatic adenocarcinoma ,precursor lesions ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Pancreatic adenocarcinoma displays a variety of molecular changes that evolve exponentially with time and lead cancer cells not only to survive, but also to invade the surrounding tissues and metastasise to distant sites. These changes include: genetic alterations in oncogenes and cancer suppressor genes; changes in the cell cycle and pathways leading to apoptosis; and also changes in epithelial to mesenchymal transition. The most common alterations involve the epidermal growth factor receptor (EGFR) gene, the HER2 gene, and the K-ras gene. In particular, the loss of function of tumor-suppressor genes has been documented in this tumor, especially in CDKN2a, p53, DPC4 and BRCA2 genes. However, other molecular events involved in pancreatic adenocarcinoma pathogenesis contribute to its development and maintenance, specifically epigenetic events. In fact, key tumor suppressors that are well established to play a role in pancreatic adenocarcinoma may be altered through hypermethylation, and oncogenes can be upregulated secondary to permissive histone modifications. Indeed, factors involved in tumor invasiveness can be aberrantly expressed through dysregulated microRNAs. This review summarizes current knowledge of pancreatic carcinogenesis from its initiation within a normal cell until the time that it has disseminated to distant organs. In this scenario, highlighting these molecular alterations could provide new clinical tools for early diagnosis and new effective therapies for this malignancy.
- Published
- 2013
- Full Text
- View/download PDF
41. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside
- Author
-
Ungaro, Antonio, primary, Tucci, Marcello, additional, Audisio, Alessandro, additional, Di Prima, Lavinia, additional, Pisano, Chiara, additional, Turco, Fabio, additional, Delcuratolo, Marco Donatello, additional, Di Maio, Massimo, additional, Scagliotti, Giorgio Vittorio, additional, and Buttigliero, Consuelo, additional
- Published
- 2022
- Full Text
- View/download PDF
42. Papillomavirus-Associated Tumor Formation Critically Depends on c-Fos Expression Induced by Viral Protein E2 and Bromodomain Protein Brd4.
- Author
-
Maria Delcuratolo, Jasmin Fertey, Markus Schneider, Johanna Schuetz, Natalie Leiprecht, Benjamin Hudjetz, Stephan Brodbeck, Silke Corall, Marcel Dreer, Roxana Michaela Schwab, Martin Grimm, Shwu-Yuan Wu, Frank Stubenrauch, Cheng-Ming Chiang, and Thomas Iftner
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Biology (General) ,QH301-705.5 - Abstract
We investigated the mechanism of how the papillomavirus E2 transcription factor can activate promoters through activator protein (AP)1 binding sites. Using an unbiased approach with an inducible cell line expressing the viral transcription factor E2 and transcriptome analysis, we found that E2 induces the expression of the two AP1 components c-Fos and FosB in a Brd4-dependent manner. In vitro RNA interference confirmed that c-Fos is one of the AP1 members driving the expression of viral oncogenes E6/E7. Mutation analysis and in vivo RNA interference identified an essential role for c-Fos/AP1 and also for the bromodomain protein Brd4 for papillomavirus-induced tumorigenesis. Lastly, chromatin immunoprecipitation analysis demonstrated that E2 binds together with Brd4 to a canonical E2 binding site (E2BS) in the promoter of c-Fos, thus activating c-Fos expression. Thus, we identified a novel way how E2 activates the viral oncogene promoter and show that E2 may act as a viral oncogene by direct activation of c-Fos involved in skin tumorigenesis.
- Published
- 2016
- Full Text
- View/download PDF
43. Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway
- Author
-
Jessica Marinello, Andrea Arleo, Marco Russo, Maria Delcuratolo, Francesca Ciccarelli, Yves Pommier, and Giovanni Capranico
- Subjects
Transcriptional Activation ,Cancer Research ,Lung Neoplasms ,Genome Integrity & Repair ,Gene Expression ,Antineoplastic Agents ,Nucleotidyltransferases ,Small Cell Lung Carcinoma ,Poisons ,DNA Topoisomerases, Type I ,Oncology ,Humans ,Genetics & Genomics ,HeLa Cells ,Computational & Systems Biology - Abstract
Background Current immunotherapy strategies have contrasting clinical results in human lung cancer patients as small-cell lung cancers (SCLC) often show features of immunological cold tumours. Topoisomerase 1 (TOP1) poisons are effective antitumor drugs with good efficacy against lung cancers. Methods We used molecular, genetic and bioinformatic approaches to determine the mechanism of micronuclei formation induced by two TOP1 poisons in different human cancer cells, including SCLC cell lines. Results TOP1 poisons stimulate similar levels of micronuclei in all tested cell lines but downstream effects can vary markedly. TOP1 poisons increase micronuclei levels with a mechanism involving R-loops as overexpression of RNaseH1 markedly reduces or abolishes both H2AX phosphorylation and micronuclei formation. TOP1 poison-induced micronuclei activate the cGAS/STING pathway leading to increased expression of immune genes in HeLa cells, but not in human SCLC cell lines, mainly due to lack of STING and/or cGAS expression. Moreover, the expression of STING and antigen-presenting machinery genes is generally downregulated in patient tumours of human lung cancer datasets. Conclusions Altogether, our data reveal an immune signalling mechanism activated by TOP1 poisons, which is often impaired in human SCLC tumours.
- Published
- 2022
- Full Text
- View/download PDF
44. New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond
- Author
-
Audisio, Alessandro, primary, Buttigliero, Consuelo, additional, Delcuratolo, Marco Donatello, additional, Parlagreco, Elena, additional, Audisio, Marco, additional, Ungaro, Antonio, additional, Di Stefano, Rosario Francesco, additional, Di Prima, Lavinia, additional, Turco, Fabio, additional, and Tucci, Marcello, additional
- Published
- 2022
- Full Text
- View/download PDF
45. Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon
- Author
-
Passiglia, Francesco, primary, Bertaglia, Valentina, additional, Reale, Maria Lucia, additional, Delcuratolo, Marco Donatello, additional, Tabbò, Fabrizio, additional, Olmetto, Emanuela, additional, Capelletto, Enrica, additional, Bironzo, Paolo, additional, and Novello, Silvia, additional
- Published
- 2021
- Full Text
- View/download PDF
46. PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study
- Author
-
Silvestris, Nicola, primary, Argentiero, Antonella, additional, Brunetti, Oronzo, additional, Sonnessa, Margherita, additional, Colonna, Fulvia, additional, Delcuratolo, Sabina, additional, Luchini, Claudio, additional, Scarpa, Aldo, additional, Lonardi, Sara, additional, Nappo, Floriana, additional, Fassan, Matteo, additional, Solimando, Antonio Giovanni, additional, Fucci, Livia, additional, and Saponaro, Concetta, additional
- Published
- 2021
- Full Text
- View/download PDF
47. Black Hairy Tongue After Immune Checkpoint Inhibitors in NSCLC: A Case Report and Review of the Literature
- Author
-
Cecchi, Cristina, primary, Mariniello, Annapaola, additional, Carnio, Simona, additional, Delcuratolo, Marco D., additional, and Novello, Silvia, additional
- Published
- 2021
- Full Text
- View/download PDF
48. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
- Author
-
Enzo Terreno, Marco Volante, Silvia Novello, Annapaola Mariniello, Désirée Deandreis, Mohsen Farsad, Marco Donatello Delcuratolo, Martina Capozza, Luisella Righi, and Virginia Liberini
- Subjects
PD-L1 ,immune PET ,Cancer Research ,PET/CT ,medicine.medical_treatment ,Review ,immune checkpoint inhibitors ,non-small cell lung carcinoma ,In vivo ,PD-1 ,medicine ,Stage (cooking) ,Lung cancer ,RC254-282 ,oncology_oncogenics ,immunotherapy ,radiomics ,biology ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Immunotherapy ,medicine.disease ,In vitro ,Oncology ,biology.protein ,Cancer research ,Molecular imaging ,business ,Ex vivo - Abstract
Simple Summary Lung cancer and in particular non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death. The development of new therapeutic approaches, including immunotherapy, has led to substantial improvement in survival time and quality of life. However, the clinical benefit of immunotherapy-based strategies is still limited to a minority of patients, reflecting the need to identify predictive biomarkers of response, which are any substance, structure, or process or its products that can be measured in the body and that can influence or predict clinical response. In this work, we provide an overview of the approved and the most promising investigational biomarkers, which have been assessed in vitro/ex vivo and in vivo, to identify patients who could benefit the most from immunotherapy-based treatment. Abstract Lung cancer remains the leading cause of cancer-related death, and it is usually diagnosed in advanced stages (stage III or IV). Recently, the availability of targeted strategies and of immunotherapy with checkpoint inhibitors (ICI) has favorably changed patient prognosis. Treatment outcome is closely related to tumor biology and interaction with the tumor immune microenvironment (TME). While the response in molecular targeted therapies relies on the presence of specific genetic alterations in tumor cells, accurate ICI biomarkers of response are lacking, and clinical outcome likely depends on multiple factors that are both host and tumor-related. This paper is an overview of the ongoing research on predictive factors both from in vitro/ex vivo analysis (ranging from conventional pathology to molecular biology) and in vivo analysis, where molecular imaging is showing an exponential growth and use due to technological advancements and to the new bioinformatics approaches applied to image analyses that allow the recovery of specific features in specific tumor subclones.
- Published
- 2021
49. Emerging insights of drug resistance in metastatic castration resistant prostate cancer
- Author
-
A. Ungaro, E. Parlagreco, R.F. Di Stefano, M. Audisio, M.D. Delcuratolo, L. Di Prima, A. Audisio, A. Samuelly, M. Tucci, and C. Buttigliero
- Published
- 2022
50. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
- Author
-
Giovanni Butturini, Roberta Marciano, Luigi Formisano, Cataldo Bianco, Eleonora Mozzillo, Anna Chiara Carratù, Sabino De Placido, Isabella Frigerio, Francesca Foschini, Priscilla Cascetta, Pietro De Placido, Roberto Bianco, Fabiana Napolitano, Antonio Santaniello, Sabina Delcuratolo, Nicola Silvestris, P. Regi, Enrico Vasile, Alberto Servetto, Caterina Vivaldi, Foschini, F., Napolitano, F., Servetto, A., Marciano, R., Mozzillo, E., Carratu, A. C., Santaniello, A., De Placido, P., Cascetta, P., Butturini, G., Frigerio, I., Regi, P., Silvestris, N., Delcuratolo, S., Vasile, E., Vivaldi, C., Bianco, C., De Placido, S., Formisano, L., and Bianco, R.
- Subjects
Oncology ,safety ,medicine.medical_specialty ,FOLFIRINOX ,lcsh:RC254-282 ,Metastasis ,gemcitabine ,pancreatic adenocarcinoma ,second line ,03 medical and health sciences ,0302 clinical medicine ,FOLFOX ,Internal medicine ,Pancreatic cancer ,Medicine ,030212 general & internal medicine ,Original Research ,business.industry ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Gemcitabine ,Oxaliplatin ,Irinotecan ,030220 oncology & carcinogenesis ,FOLFIRI ,business ,FOLFIRINOX, gemcitabine, pancreatic adenocarcinoma, safety, second line ,medicine.drug - Abstract
Background: Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death. In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy regimens are considered the standard of care. However, the optimal sequence of these regimens is unclear. Methods: This retrospective study initially evaluated 186 patients with locally advanced/metastatic pancreatic cancer at three Italian institutions between February 2013 and October 2019. All patients had progressed after receiving gemcitabine-based first-line chemotherapy and were subsequently offered second-line FOLFIRINOX, FOLFOX-6, or FOLFIRI treatment. This study evaluated progression-free survival (PFS), overall survival from the start of second-line treatment (OS2), overall survival from the start of first-line treatment (OS1), and safety outcomes. Results: A total of 77 patients received ⩾4 cycles of second-line chemotherapy and were considered eligible: 15 patients received FOLFIRINOX, 32 patients received FOLFOX-6, and 30 patients received FOLFIRI. The FOLFIRINOX group had median PFS of 26.29 weeks and median OS2 of 47.86 weeks, while the FOLFIRI group had median PFS of 10.57 weeks and median OS2 of 25.00 weeks ( p = 0.038). No significant differences were observed between the FOLFIRINOX and FOLFOX-6 groups in terms of PFS (26.29 weeks versus 23.07 weeks) or OS2 (47.86 weeks versus 42.00 weeks). The most common grade 3–4 toxicities were anemia, neutropenia, and thrombocytopenia, which occurred more frequently in the FOLFIRINOX and FOLFOX-6 groups. Conclusion: Relative to the FOLFIRI regimen, the FOLFIRINOX regimen had a favorable toxicity profile and better survival outcomes. No significant differences were observed relative to the FOLFOX-6 regimen.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.